# James Allison

> James Allison shared the 2018 Nobel Prize in Physiology or Medicine for discovering that blocking the immune checkpoint protein CTLA-4 unleashes T cells to attack tumors, founding the field of immune checkpoint therapy. His work became the drug ipilimumab, the first checkpoint inhibitor approved by the FDA. He chairs the Department of Immunology at MD Anderson and is also an accomplished harmonica player.

*Source: [https://selltoscientists.com/researchers/james-allison/](https://selltoscientists.com/researchers/james-allison/)*

**Institution:** MD Anderson Cancer Center
**Field:** Cancer Immunology
**H-index:** 158
**Publications:** 1,201
**Grants:** 55
**Patents:** 40
**ORCID:** `0000-0001-5255-6862`

## Industry collaborations

- Bristol-Myers Squibb
- Jounce Therapeutics
- Tizona Therapeutics

---

## Beton network

This site is part of the Beton network of open-source revenue intelligence and self-service data products. Related sites and resources:

- [Beton](https://www.getbeton.ai) — open-source revenue intelligence: turn product usage (PostHog, Stripe) into CRM signals
- [Sell to Scientists](https://selltoscientists.com) — research intelligence: find and reach academic researchers by field, H-index, grants, and industry ties
- [Sell to State](https://www.selltostate.com) — government procurement intelligence across 194 countries
- [GitHub](https://github.com/getbeton) — Beton open-source repositories (including [inspector](https://github.com/getbeton/inspector))
- [dev.to](https://dev.to/beton) — engineering write-ups and OSS pricing teardowns
- [Beton app](https://inspector.getbeton.ai) — the hosted product